Coherus Oncology 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, so welcome to the first session of the second day of the Guggenheim Conference. My name is Paul Jeng. I am a biotech analyst with Guggenheim, and I am very pleased to welcome our first company of the day to kick things off, Coherus Oncology. And with us today is Denny Lanfear, President and CEO, Raj Diaz, CMO, Theresa LaVallee, Chief Scientific and Development Officer. Thank you all for joining.
Thank you, Paul. It is good to be with you today, and we appreciate the bank inviting us to the conference.
Great. So, maybe just to kick things off for those who might be newer to the story, could you provide a quick introduction to the company and the current pipeline and commercial product?
Sure. So a couple years ago, we acquired Surface Oncology and then set about divesting our biosimilar business, which went pretty well. We did about $800 million in divestitures and paid off almost $500 million in debt. We dropped $250 million onto the balance sheet and set about the task of developing tagmokitug, our CCR8 Treg depleter, and also casdozokitug, our anti-IL-27. We had a very broad clinical plan for tagmokitug, which encompassed a number of tumors, esophageal first line, second line, head and neck, various gastric tumors, and even fourth line CRC. What we are very happy with now is having cast our net so broadly, we are able now to focus on esophageal.
This is something I think where Dr. Dias subsequently will talk about the data, but it allows us really to strategically focus the organization in a way that we haven't been able to do before. We've taken one particular disease focus, first-line and second-line esophageal, and now we're going to pursue various accelerated approaches, particularly in second-line with a priority. The strategic prioritization has a number of other benefits for us. First of all, it's very expensive, and there's a lot of overhead in pursuing so many clinical indications concurrently. By focusing, we're able really to put ourselves in a position where we can reduce the organization. At the same time, a couple other very fortuitous things happened.
From the divestiture, we had transition services agreements with the acquirer, Intas Accord, and those are all now winding down, and that actually inflated our burn a bit. I think it was a little confusing for investors, but now we're in a position where we don't have to deal with that. The third fortuitous thing which occurred is that we have now completed our process transfer of toripalimab, our PD-1, from China to the U.S. So that overhead and that burn also is being dramatically reduced. All three of these things allowed us really to right-size the organization here. We are putting in place a 30% headcount reduction that's primarily across the non-commercial side of the business and focusing very, very tightly on esophageal and where we can go.
I'll let Raj talk about the data as indicated, but what I like about esophageal is that it's a very large market ex-U.S. It's the sixth leading cause of cancer deaths, and there's over 400,000 patients annually ex-U.S., particularly in Asia. One of our strategies we've talked about for some time is the partnering and being able to bring in partnering funds, offset clinical costs, expenses, and then have partners, of course, contribute to future clinical development costs. Now that we have an indication and we have very strong data, now we're able to go and look for partners for tagmokitug, and we actually have a financial advisor that we're signing up to go and help us with that. That's all worked really, really well.
The other thing that I would note about the reductions in the organization and the savings is they amount to about $6 million or $7 million a quarter, and that has duration to it. What we're going to do really is now we're able to drive the company to core burn break-even a little earlier. One of the things we're focusing on is driving the sales of LOQTORZI up from $14 million or $15 million up to $25 million, $30 million, or $35 million, at which point the core burn, which is basically the overhead and the cost and so forth without the clinical trials, that'll be taken care of. I think that's very exciting because that way it puts us in a self-sufficiency mode where we're going. Just back to the data for a moment, I think it's very exciting data.
The mechanism of action for Treg depletion now is coming very clear. Dr. LaVallee can talk a little bit about that. I think we are very pleased with the way things are working out for us.
Great. So yeah, lots to chew on there, but it is great to talk to you guys after you provided such a meaningful clinical update as well as strategic update. Maybe starting with the clinical part of things, we recently saw the data for Tagmo across a basket of solid tumor indications, and you have announced you are prioritizing esophageal. Can you sort of walk us through what you saw in that update and why the decision to prioritize esophageal?
Yeah. Good morning, Paul. No, thank you. Let me just take a step back, first of all. We ran a very intentional program where we looked at five different tumor settings associated with mucosal immunity, where the prevalence of Treg, CCR8-positive Tregs was high. Really, our intention overall with this TREGCHECK program was to do two things. Number one, show activity and see where we had activity, and secondly, to really see where the activity was strongest, where we can then progress further in terms of development. Broadly speaking, we learned three things with the program. First of all, that we can reverse in the second-line setting in PD-1 experienced patients, that we can reverse PD-1 resistance. Secondly, we also learned that in the first-line setting, so earlier- that we could enhance anti-tumor activity in combination with chemotherapy, which is, of course, important, right?
Because we know that the immune system is more active in the first-line setting or in earlier lines. Thirdly, we also learned that in colder tumors, so PD-L1 low, PD-L1 negative colorectal cancer, for example, that we could activate the immune system. Broadly, we learned from this program, we did see activity across all of the different tumor settings that we looked at, which was very positive. Our strongest signal, as you alluded to, was in esophageal cancer. Let me just briefly take you through the data. In first-line esophageal squamous cell, we saw eight out of nine of the evaluable patients responded, including one complete response, which is pretty encouraging. That equated to an 89% ORR. Just for benchmarks purposes, the current standard of care is a PD-1 plus chemotherapy that is only in PD-L1 positive patients.
Their ORR is roughly in the range of 44%-60%, depending on which trial and which agent you are looking at. Ours was 89% overall. It was 100% for PD-L1 positive patients, so obviously very encouraging there, despite being a small patient number. So strong signal in first line. In second line, if we looked at both the esophageal squamous histology as well as the esophageal adenocarcinoma histology, and this is an area of huge unmet medical need. As we looked at both of those histologies in the second-line setting, we saw overall, out of nine evaluable patients, we saw three partial responses, so a 33% ORR. If we added in the additional unconfirmed partial response as well, that then went up to 44%.
Again, the benchmarks for this kind of setting is essentially chemotherapy, and that is around the 10% ORR range, typically between two to four months PFS, median PFS. Again, whilst our data is not yet fully mature, we showed a median PFS of the range of 5.5 months or thereabouts. Durability is important, so that is a very important metric. If we also look at the, we have talked about the clinical benefit rate, which is CR plus PR plus six months of stable disease. The overall CBR rate was in the region of 55%, so also pretty encouraging. That is an overall summary of the data and the focus in on esophageal specifically. I think we are able to plant our flag now in esophageal overall, first line, second line, area of huge unmet medical need. Denny talked about the overall patient population, which globally is very large.
I think that is really where we are progressing initially with a focus in on second line, because I think, again, for three reasons. First of all, there is a huge unmet medical need. There is a potential fast path to approval, potentially leveraging some of the accelerated FDA designations, and of course, the signal as well.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
